MEHMET ÖZALEVLİ

Dr. MEHMET ÖZALEVLİ

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in International Journal Of Impotence Research
Verified
Journal Article
Closed access
PDF file
SGS. Gonultas
S. Gonultas
SKS. Kardas
S. Kardas
MGM. Gelmis
M. Gelmis
AKA. H. Kinik
A. H. Kinik
MÖMEHMET ÖZALEVLİ
MEHMET ÖZALEVLİ
BAB. Arslan
B. Arslan

22 November 2022 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
GYGokhan Yazici
Gokhan Yazici
EGErsin Gokmen
Ersin Gokmen
MKMustafa Gokhan Kose
Mustafa Gokhan Kose
BÇBuğra Çetin
Buğra Çetin
BABurak Arslan
Burak Arslan
EOEnver Ozdemir
Enver Ozdemir

29 May 2026 in Endouroloji Bulteni
Verified
Journal Article
Closed access
MGMücahit Gelmiş
Mücahit Gelmiş
AAAli Ayten
Ali Ayten
MÖMEHMET ÖZALEVLİ
MEHMET ÖZALEVLİ
HCHakan Ceylan
Hakan Ceylan
KMKanan Maharramov
Kanan Maharramov
SBSibel Bektaş
Sibel Bektaş
Objective: To evaluate the prognostic impact of pT1a–pT1b substaging on recurrence and progression in patients with high-grade T1 bladder cancer and to determine whether substaging serves as an independent predictor when assessed alongside established clinical and pathological risk factors.Materials and Methods: This retrospective, single-center cohort study included patients diagnosed with high-grade pT1 urothelial carcinoma who underwent TURBT between January 2017 and March 2025. Cases with ≥pT2 disease, other malignancies, BCG contraindications, treatment non-compliance, incomplete follow-up, or trigonal tumors with unreliable muscularis mucosa assessment were excluded. Demographic, clinical, pathological, and follow-up data were extracted from institutional records. Recurrence and progression were defined according to standard criteria. Substaging was performed by experienced uropathologists. Survival outcomes were analyzed using the Kaplan–Meier method, and independent predictors were identified by multivariate Cox regression.Results: Of 152 patients, 110 (72.4%) were classified as pT1a and 42 (27.6%) as pT1b. CIS and tumor size ≥3 cm were significantly more frequent in pT1b cases. In multivariate analysis, CIS and tumor size ≥3 cm were independent predictors of both recurrence and progression. Although pT1b substaging was associated with worse recurrence-free survival on Kaplan–Meier analysis, it was not an independent predictor of recurrence in the Cox model; however, it independently predicted progression (HR=3.38). Kaplan–Meier analyses also demonstrated significantly worse progression-free survival in the pT1b group.Conclusion: pT1 substaging, particularly the identification of pT1b disease, provides meaningful prognostic information for progression in high-grade T1 bladder cancer. Integrating substaging with key pathological factors such as CIS and tumor size may improve individualized risk stratification and support early risk-adapted treatment decisions.

17 April 2026 in Precision Oncology
Verified
Journal Article
Open access
PDF file
ABAndreia Bilé-Silva
Andreia Bilé-Silva
MÖMEHMET ÖZALEVLİ
MEHMET ÖZALEVLİ
GCGabriel Chan
Gabriel Chan
SASyed Ahmed
Syed Ahmed
ZTZafer Tandogdu
Zafer Tandogdu
Background/Objectives: Prostate cancer (PCa) incidence is rising, with radical prostatectomy (RP) as the main curative surgery for localised cases, which includes removing seminal vesicles (SV). SV invasion (SVI) predicts poor oncological outcomes, making accurate preoperative staging to identify SVI crucial for surgical planning. This ensures oncological safety by enabling wide excision when needed, while preserving tissue to maintain function. This review synthesises current evidence on pre-biopsy MRI findings and/or clinicopathological parameters to diagnose SVI in PCa. Methods: A literature search (2005–2025) using OVID for studies assessing pre-biopsy MRI findings, with a priori eligibility for clinicopathological or combined MRI–clinicopathological models (index tests), for detecting SVI (outcome) compared to RP histopathology (standard reference) in patients with primary localised PCa (patients). This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Risk of bias was evaluated with QUADAS-2, and pooled diagnostic accuracy metrics and study heterogeneity were analysed. Results: Five studies qualified, while three used binary mpMRI classification and were quantitatively analysed. No eligible studies assessed clinicopathological predictors or combined MRI–clinicopathological models; all included studies evaluated pre-biopsy MRI findings only, and none included high-dimensional radiomics. The pooled sensitivity was 0.66 (95% CI: 0.52–0.78), specificity 0.94 (0.89–0.97), positive predictive value (PPV) 0.76 (0.60–0.87), negative predictive value (NPV) 0.92 (0.85–0.94), and diagnostic odds ratio 30.13 (12.36–73.47), with moderate heterogeneity. All included studies were retrospective cohorts with considerable risk of bias. Conclusions: In the small number of heterogeneous, single-centre retrospective studies available, pre-biopsy MRI findings show high specificity and NPV for preoperative detection of SVI but only moderate sensitivity, which limits its reliability as a standalone tool. The pooled diagnostic accuracy estimates should be interpreted as exploratory. These findings should therefore be interpreted cautiously. Future studies must integrate MRI with clinicopathological data, addressing this key evidence gap before firm conclusions can be drawn or clinical practice changed.

27 August 2021 in Üroonkoloji Bülteni
Verified
Journal Article
Closed access
OÖOktay Özman
Oktay Özman
GYGökhan Yazıcı
Gökhan Yazıcı
MÖMEHMET ÖZALEVLİ
MEHMET ÖZALEVLİ
EGErsin Gökmen
Ersin Gökmen
SGSerkan Gönültaş
Serkan Gönültaş
BABurak Arslan
Burak Arslan

16 December 2025 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
AAAli Ayten
Ali Ayten
MKMert Kahraman
Mert Kahraman
OCOguzhan Cura
Oguzhan Cura
MÖMEHMET ÖZALEVLİ
MEHMET ÖZALEVLİ
MGMucahit Gelmis
Mucahit Gelmis
SKSina Kardas
Sina Kardas